Company Overview and News

Thundelarra strengthens board with new director

Crabb practised as a solicitor from 1980 to 2004 specialising in mining, corporate and commercial law.

Golden Rim Resources bags $1.27M for flagship gold project in Burkina Faso

Golden Rim Resources Ltd. (ASX:GMR) has raised $1.27 million via a rights issue to fund the drilling program at its flagship Kouri Gold Project in Burkina Faso.

Target Energy and Golden Rim Resources are early fallers as investors trade the spread

Target Energy Ltd (ASX:TEX) and Golden Rim Resources Ltd (ASX:GMR) are early fallers on the ASX during Monday.

Annual Report and Accounts

2017-06-30 londonstockexchange
The qualified pleasure arises from the fact that 2016 was a challenging year for the Company with the severe downturn in the copper price impacting negatively on equity raising opportunities.  The poor equity market conditions resulted in the Company continuing its rationalisation process with a focus on expenditure.  Chilean manpower and corporate manpower were reduced so that the organisation can be better aligned with its early stage exploration assets.

Golden Rim Resources shares rise on acquiring the Kouri Gold Project

Golden Rim Resources (ASX:GMR) has fully acquired the Kouri Gold Project in Burkina Faso by purchasing the interest held by Epsilon Gold Mines.

Half-year Report

2016-09-29 londonstockexchange
Herencia Resources plc is pleased to announce the unaudited half-yearly accounts of the Company and its subsidiaries (the "Group") for the six months ended 30 June 2016.

General Update

2016-09-16 londonstockexchange
As part of the Board restructure and Corporate Reinvigoration strategy ("the Strategy") announced on 27 July 2016, the Company is working with interested parties with the aim of providing additional funds to progress the Company's Picachos Project (Cu-Ag) and for working capital requirements. As part of the Strategy, the Company is looking to use these funds to move Picachos closer to a decision to mine or provide the foundations for potential joint venture scenarios given recent interest in the project.

Think zinc: miners bet big on revival in key base metal market

2016-08-24 reuters
SYDNEY, Aug 24 Resource companies are racing to dig zinc mines, betting that markets for the metal used to rust-proof steel and protect noses from sunburn have finally turned after a decade in the doldrums.

Herencia Completes Paguanta Sale

2016-07-28 londonstockexchange
Ø The Company has executed a formal purchase agreement ("Agreement") with Golden Rim Resources Limited ("GMR") for the sale of its 70% ownership in the Paguanta zinc, silver and lead Project in northern Chile.

Final Results

2016-07-18 londonstockexchange
Whilst it has been a difficult operating environment for junior resources companies, I am glad to be able to update shareholders on the Company's activities during the financial year ended December 2015.

Update - sale of Paguanta

2016-07-04 londonstockexchange
Herencia Resources plc (AIM: HER) refers to its previous announcement with respect to its intention to dispose of the Company's 70% equity in the Paguanta Project. On 10 May 2016, the Company announced they had entered into a transaction ("Proposed Transaction") with Golden Rim Resources (ASX:GMR) under which the Company will sell all of the issued shares in Paguanta Resources (Chile) SA ("PRC"), a wholly owned subsidiary of Herencia.

Golden Rim Resources Ltd tops ASX % Gainers intra-day

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Formal Documentation for Sale of Paguanta

2016-06-15 londonstockexchange
Herencia Resources plc (AIM: HER) is pleased to announced that it has executed formal documentation for the sale of the Company's 70% equity in the Paguanta Project on the terms set out in the announcement dated 10 May 2016.

Update on the Sale of Paguanta

2016-06-07 londonstockexchange
Herencia Resources plc (AIM: HER) refers to the announcement made on 10 May 2016 regarding a proposed transaction under which the Company will dispose of ("Proposed Transaction") all of the issued shares in Paguanta Resources (Chile) SA ("PRC"), a wholly owned subsidiary of Herencia Resources plc's ("Herencia", "Company") to Golden Rim Resources Limited ("Golden Rim").  PRC holds 70% of the shares in Compania Minera Paguanta S.

Herencia Secures up to US$150,000 Funding

2016-06-07 londonstockexchange
Herencia is pleased to announce that today it has executed legally binding term sheets with two of its shareholders,  the Australian Special Opportunity Fund ("Lind Partners") and Oriental Darius Co. Ltd ("Oriental" and, together with Lind Partners, the "Shareholders") to advance the Company up to US$150,000.    The funds will be provided by the Shareholders and will be divided into two Tranches (Tranche 1 totalling $50,000 and Tranche 2 totalling $100,000).

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...